Journal article
Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.
- Abstract:
-
IAVI-006 was the first large randomised, double-blinded, placebo-controlled Phase I clinical trial to systematically investigate the prime-boost strategy for induction of HIV-1 specific CD8+ cytotoxic T-lymphocytes (CTL) in a factorial trial design using (i) priming with 0.5 mg or 2 mg of pTHr.HIVA DNA vaccine, followed by (ii) two booster vaccinations with 5 x 10(7) MVA.HIVA at weeks 8 and 12 (early boost) or weeks 20 and 24 (late boost). This study set the basis for later clinical trials an...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- Vaccine More from this journal
- Volume:
- 26
- Issue:
- 51
- Pages:
- 6671-6677
- Publication date:
- 2008-12-01
- DOI:
- EISSN:
-
1873-2518
- ISSN:
-
0264-410X
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:3216
- UUID:
-
uuid:73a619b2-6c84-4f68-91f0-ee6de974023b
- Local pid:
-
pubs:3216
- Source identifiers:
-
3216
- Deposit date:
-
2012-12-19
Terms of use
- Copyright date:
- 2008
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record